troglitazone has been researched along with Hypertension in 37 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the effects of troglitazone, an agent used to treat insulin resistance, on cardiac sympathetic nervous dysfunction and insulin resistance in patients with essential hypertension." | 9.11 | Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension. ( Hamada, M; Ikeda, S; Inaba, S; Kohara, K; Komatsu, J; Kurata, M; Sueda, S; Suzuki, J; Watanabe, K, 2004) |
| " Troglitazone (CS-045) is a newly developed antidiabetic agent that enhances insulin sensitivity." | 9.08 | Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. ( Ikegami, H; Masuo, K; Mikami, H; Ogihara, T; Rakugi, H, 1995) |
| "Body weight and BP decreased significantly in the diet group but not in the troglitazone group at the end of the intervention periods." | 7.71 | Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. ( Kamide, K; Kawano, Y; Minami, J; Tsunoda, S, 2002) |
| " When results for patients with and without hypertension were separately analyzed, a significant improvement in SMGU after troglitazone was seen in both normotensive and hypertensive patients (normotensive [n = 10]: baseline, 3." | 7.71 | Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients. ( Inoue, Y; Momose, T; Moritan, T; Nagai, R; Ohtomo, K; Tateno, M; Yokoyama, I; Yonekura, K, 2001) |
| "To examine the effects of troglitazone, an agent used to treat insulin resistance, on cardiac sympathetic nervous dysfunction and insulin resistance in patients with essential hypertension." | 5.11 | Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension. ( Hamada, M; Ikeda, S; Inaba, S; Kohara, K; Komatsu, J; Kurata, M; Sueda, S; Suzuki, J; Watanabe, K, 2004) |
| " Troglitazone (CS-045) is a newly developed antidiabetic agent that enhances insulin sensitivity." | 5.08 | Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. ( Ikegami, H; Masuo, K; Mikami, H; Ogihara, T; Rakugi, H, 1995) |
| " Metformin and troglitazone, approved for use in the treatment of type 2 diabetes mellitus (DM), improve insulin sensitivity and lower plasma glucose concentrations." | 4.80 | Insulin resistance syndrome: options for treatment. ( Fonseca, VA; Granberry, MC, 1999) |
| "Troglitazone, a newly introduced insulin sensitizer, has been implicated in prevention and treatment of atherosclerotic cardiovascular disease especially associated with type 2 diabetes mellitus and insulin resistance." | 4.80 | [Cardiovascular effects of the thiazolidinedione troglitazone]. ( Kuzuya, H; Nakano, T; Yamada, K, 2000) |
| " Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure." | 4.79 | [Treatment of hypertension associated with diabetes mellitus]. ( Katayama, S, 1997) |
| "To investigate the effects of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand on angiotensin II (AngII)-induced endothelin-1 (ET-1) and NO secretion by endothelial cells in comparison with AngII type I receptor (AT1R) antagonist losartan, so as to reveal the relationship between PPAR gamma and essential hypertension." | 3.74 | [Peroxisome proliferator-activated receptor activator troglitazone inhibits angiotensin II-stimulated secretion of vasoactive factors by endothelial cells]. ( Li, YQ; Niu, XL; Wang, CX; Wang, SJ; Wei, J; Zhou, J, 2007) |
| "Body weight and BP decreased significantly in the diet group but not in the troglitazone group at the end of the intervention periods." | 3.71 | Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. ( Kamide, K; Kawano, Y; Minami, J; Tsunoda, S, 2002) |
| " When results for patients with and without hypertension were separately analyzed, a significant improvement in SMGU after troglitazone was seen in both normotensive and hypertensive patients (normotensive [n = 10]: baseline, 3." | 3.71 | Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients. ( Inoue, Y; Momose, T; Moritan, T; Nagai, R; Ohtomo, K; Tateno, M; Yokoyama, I; Yonekura, K, 2001) |
| " In the present study, we used Otsuka Long-Evans Tokushima Fatty (OLETF) rats, which exhibit hypertension, obesity, severe hyperglycemia and hypertriglyceridemia, and are thus considered an animal model of atherogenic disease, to test the effects of oral administration of troglitazone (200 mg/kg) on renal klotho mRNA expression and endothelial function." | 3.71 | Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. ( Kanai, H; Kurabayashi, M; Kuro-o, M; Nabeshima, Y; Nagai, R; Nakamura, T; Saito, Y; Sumino, H; Takeda, S; Yamagishi, T, 2001) |
| "An open study comparing the effects of weight reduction by low-energy diet and treatment with troglitazone, an insulin-sensitizing agent." | 3.70 | Effects of a low-energy diet and an insulin-sensitizing agent on ambulatory blood pressure in overweight hypertensive patients. ( Kawano, Y; Minami, J; Okuda, N; Omae, T; Takishita, S, 2000) |
| "Both the lard and sucrose enrichment increased SBP and body weight compared with controls." | 3.70 | Dietary fat-induced increase in blood pressure and insulin resistance in rats. ( Hotta, N; Iguchi, A; Miura, H; Nakamura, J; Tamagawa, T; Tamaya, N; Uemura, K; Yoshioka, S, 2000) |
| "Treatment with metformin was less effective than lifestyle modifications, resulting in an average reduction of risk for development of type 2 diabetes by 31% compared with placebo." | 2.42 | [Progress in the prevention of type 2 diabetes]. ( Schernthaner, G, 2003) |
| "Insulin resistance syndrome is the theory that glucose intolerance, hyperinsulinemia, increased very low density lipoprotein triglyceride level, decreased high density lipoprotein cholesterol level, and hypertension are proposed consequences of insulin resistance." | 2.41 | [Insulin sensitizer and hypertension]. ( Shimamoto, K, 2000) |
| "In these populations, NIDDM may be present in 10% to as much as 50% of the adult population." | 2.40 | [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations]. ( Flórez, H, 1997) |
| "Moreover, hypertension was reported to be a possible cause of insulin resistance." | 2.40 | [Insulin, as a regulating factor of blood pressure]. ( Hamada, Y; Ikegami, H; Ogihara, T, 1997) |
| "In conclusion, improvement of hyperinsulinemia can decrease NHE activity and blood pressure in fructose-fed BHR." | 1.32 | Troglitazone reduces activity of the Na+/H+ exchanger in fructose-fed borderline hypertensive rats. ( Fujioka, Y; Iwasaki, T; Masai, M; Morimoto, S; Ohyanagi, M; Okumura, T; Tsuboi, S; Tsujino, T, 2003) |
| "Patients with NIDDM have excessive cardiovascular morbidity and mortality, even in the absence of hypertension." | 1.31 | Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients. ( Abe, N; Hirayama, H; Makino, N; Sugano, M; Yonemoch, H, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (27.03) | 18.2507 |
| 2000's | 27 (72.97) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Tsunoda, S | 1 |
| Kamide, K | 1 |
| Minami, J | 2 |
| Kawano, Y | 2 |
| Fujioka, Y | 1 |
| Masai, M | 1 |
| Tsuboi, S | 1 |
| Okumura, T | 1 |
| Morimoto, S | 1 |
| Tsujino, T | 1 |
| Ohyanagi, M | 1 |
| Iwasaki, T | 1 |
| Schröder, AK | 1 |
| Tauchert, S | 1 |
| Ortmann, O | 1 |
| Diedrich, K | 1 |
| Weiss, JM | 1 |
| Schernthaner, G | 1 |
| Wakino, S | 1 |
| Hayashi, K | 1 |
| Kanda, T | 1 |
| Tatematsu, S | 1 |
| Homma, K | 1 |
| Yoshioka, K | 1 |
| Takamatsu, I | 1 |
| Saruta, T | 1 |
| Grassi, G | 1 |
| Ritz, E | 1 |
| Watanabe, K | 1 |
| Komatsu, J | 1 |
| Kurata, M | 1 |
| Inaba, S | 1 |
| Ikeda, S | 1 |
| Sueda, S | 1 |
| Suzuki, J | 1 |
| Kohara, K | 1 |
| Hamada, M | 1 |
| Atkins, KB | 1 |
| Northcott, CA | 1 |
| Watts, SW | 1 |
| Brosius, FC | 1 |
| Laakso, M | 1 |
| Sarafidis, PA | 1 |
| Nilsson, PM | 1 |
| Li, YQ | 1 |
| Niu, XL | 1 |
| Wang, CX | 1 |
| Wei, J | 1 |
| Wang, SJ | 1 |
| Zhou, J | 1 |
| Ogihara, T | 2 |
| Rakugi, H | 1 |
| Ikegami, H | 2 |
| Mikami, H | 1 |
| Masuo, K | 1 |
| Katayama, S | 2 |
| Abe, M | 1 |
| Kashiwabara, H | 1 |
| Kosegawa, I | 1 |
| Ishii, J | 1 |
| Kawaguchi, M | 1 |
| Tanigawa, K | 1 |
| Kato, Y | 1 |
| Flórez, H | 2 |
| Hamada, Y | 1 |
| Lisi, DM | 1 |
| Casanova, P | 1 |
| Sonnenberg, GE | 1 |
| Kotchen, TA | 1 |
| Granberry, MC | 1 |
| Fonseca, VA | 1 |
| Shimamoto, K | 1 |
| Iwatani, M | 1 |
| Wasada, T | 1 |
| Iwamoto, Y | 1 |
| Kamatani, N | 1 |
| Yamada, K | 1 |
| Kuzuya, H | 1 |
| Nakano, T | 1 |
| Garg, R | 1 |
| Kumbkarni, Y | 1 |
| Aljada, A | 1 |
| Mohanty, P | 1 |
| Ghanim, H | 1 |
| Hamouda, W | 1 |
| Dandona, P | 1 |
| Naruse, M | 1 |
| Yoshimoto, T | 1 |
| Tanabe, A | 1 |
| Takagi, S | 1 |
| Tago, K | 1 |
| Takano, K | 1 |
| Okuda, N | 1 |
| Takishita, S | 1 |
| Omae, T | 1 |
| Yoshioka, S | 1 |
| Uemura, K | 1 |
| Tamaya, N | 1 |
| Tamagawa, T | 1 |
| Miura, H | 1 |
| Iguchi, A | 1 |
| Nakamura, J | 1 |
| Hotta, N | 1 |
| Hirayama, H | 2 |
| Sugano, M | 1 |
| Abe, N | 2 |
| Yonemoch, H | 1 |
| Makino, N | 2 |
| Yoshida, K | 1 |
| Kohzuki, M | 1 |
| Xu, HL | 1 |
| Wu, XM | 1 |
| Kamimoto, M | 1 |
| Sato, T | 1 |
| Yokoyama, I | 1 |
| Yonekura, K | 1 |
| Moritan, T | 1 |
| Tateno, M | 1 |
| Momose, T | 1 |
| Ohtomo, K | 1 |
| Inoue, Y | 1 |
| Nagai, R | 2 |
| Marcus, AO | 1 |
| Nakamura, T | 2 |
| Funahashi, T | 1 |
| Yamashita, S | 1 |
| Nishida, M | 1 |
| Nishida, Y | 1 |
| Takahashi, M | 1 |
| Hotta, K | 1 |
| Kuriyama, H | 1 |
| Kihara, S | 1 |
| Ohuchi, N | 1 |
| Nishimura, T | 1 |
| Kishino, BI | 1 |
| Ishikawa, K | 1 |
| Kawamoto, T | 1 |
| Tokunaga, K | 1 |
| Nakagawa, C | 1 |
| Mineo, I | 1 |
| Watanabe, F | 1 |
| Tarui, S | 1 |
| Matsuzawa, Y | 1 |
| Yamagishi, T | 1 |
| Saito, Y | 1 |
| Takeda, S | 1 |
| Kanai, H | 1 |
| Sumino, H | 1 |
| Kuro-o, M | 1 |
| Nabeshima, Y | 1 |
| Kurabayashi, M | 1 |
| Yonemochi, H | 1 |
| Yano, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488] | Phase 4 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
17 reviews available for troglitazone and Hypertension
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
[Insulin resistance in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Chromans; Controlled Clinical Trials as | 2003 |
[Progress in the prevention of type 2 diabetes].
Topics: Acarbose; Adult; Alcohol Drinking; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Chromans | 2003 |
Cardiovascular and sympathetic effects of reversing insulin resistance in hypertension.
Topics: Chromans; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Sympathetic Nervous System; | 2004 |
PPARgamma agonists: killing two birds with one stone?
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypertension; Hypoglycemic Agents; PPAR gamma; Thiazoli | 2004 |
Prevention of type 2 diabetes.
Topics: Acarbose; Birth Weight; Blood Glucose; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2 | 2005 |
The effects of thiazolidinediones on blood pressure levels - a systematic review.
Topics: Blood Pressure; Chromans; Humans; Hypertension; MEDLINE; Pioglitazone; Rosiglitazone; Thiazolidinedi | 2006 |
[Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
Topics: Adult; Aged; Chromans; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing | 1997 |
[Insulin, as a regulating factor of blood pressure].
Topics: Animals; Cell Division; Chromans; Humans; Hyperinsulinism; Hypertension; Hypoglycemic Agents; Insuli | 1997 |
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chroma | 1997 |
New therapeutic approaches to reversing insulin resistance.
Topics: Animals; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Humans; Hypertension; Hypogly | 1998 |
Insulin resistance syndrome: options for treatment.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipid | 1999 |
[Insulin sensitizer and hypertension].
Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Chromans; Humans; Hyperinsulinism; Hypertension; Hypogl | 2000 |
[Insulin sensitizer and urate metabolism].
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Glucose; Gout; Humans; Hyperlipidemias; Hypertension; H | 2000 |
[Cardiovascular effects of the thiazolidinedione troglitazone].
Topics: Animals; Arteriosclerosis; Cardiovascular Diseases; Cardiovascular System; Chromans; Diabetes Mellit | 2000 |
[Insulin-sensitizing agents and hypertension].
Topics: Animals; Chromans; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thia | 2000 |
Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
Topics: Acarbose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Human | 2000 |
4 trials available for troglitazone and Hypertension
| Article | Year |
|---|---|
Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension.
Topics: Antihypertensive Agents; Blood Glucose; Chromans; Female; Heart; Humans; Hypertension; Hypertrophy, | 2004 |
Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.
Topics: Aged; Blood Glucose; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Female; Heart Rate; Hemogl | 1995 |
Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial.
Topics: Adipose Tissue; Blood Glucose; Blood Pressure; Body Composition; Cholesterol; Chromans; Double-Blind | 2001 |
Cardiac hypertrophy in diabetes patients with and without hypertension: effects of troglitazone, a novel antidiabetic drug, on diastolic function.
Topics: Cardiomegaly; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diastole; Female; Humans; | 2001 |
16 other studies available for troglitazone and Hypertension
| Article | Year |
|---|---|
Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Pressure; Body Weight; Caloric Restriction; Chroma | 2002 |
Troglitazone reduces activity of the Na+/H+ exchanger in fructose-fed borderline hypertensive rats.
Topics: Animals; Bezafibrate; Blood Glucose; Blood Platelets; Blood Pressure; Calcium; Chromans; Diet; Eicos | 2003 |
Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2.
Topics: Angiotensin II; Animals; Blood Pressure; Cell Cycle Proteins; Cells, Cultured; Chromans; Hypertensio | 2004 |
Effects of PPAR-gamma ligands on vascular smooth muscle marker expression in hypertensive and normal arteries.
Topics: Animals; Aorta; Arteries; Biomarkers; Blood Pressure; Carotid Arteries; Chromans; Deoxyglucose; Deso | 2005 |
[Peroxisome proliferator-activated receptor activator troglitazone inhibits angiotensin II-stimulated secretion of vasoactive factors by endothelial cells].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Line | 2007 |
Evidence against a role of insulin in hypertension in spontaneously hypertensive rats. CS-045 does not lower blood pressure despite improvement of insulin resistance.
Topics: Animals; Blood Glucose; Blood Pressure; Chromans; Glucose; Homeostasis; Hypertension; Insulin; Insul | 1994 |
A study of effect of CS-045, a new antidiabetic drug, on hypertension in spontaneously hypertensive rat.
Topics: Animals; Blood Glucose; Blood Pressure; Chromans; Hypertension; Hypoglycemic Agents; Insulin; Insuli | 1995 |
Troglitazone: monotherapy indication.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Chromans; Diabetes Mellitus, Type 2; Drug | 1998 |
[Changes in clinical intervention studies: when the wellbeing of the patients takes precedence].
Topics: Antihypertensive Agents; Chromans; Clinical Trials as Topic; Diabetes Complications; Enalapril; Ethi | 1998 |
Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects.
Topics: Adult; Antioxidants; Brachial Artery; Chromans; Female; Humans; Hypertension; Ischemia; Leukocytes, | 2000 |
Effects of a low-energy diet and an insulin-sensitizing agent on ambulatory blood pressure in overweight hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Chromans; Diet, Reducing; Female; Humans; Hypertension; Hypoglycemic Ag | 2000 |
Dietary fat-induced increase in blood pressure and insulin resistance in rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Blood Pressure; Body Weight; Chromans; Dietary Carbohydrates | 2000 |
Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients.
Topics: Blood Flow Velocity; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chromans; | 2001 |
Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Chromans; Humans; Hypertension; H | 2001 |
Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Fluorodeoxyg | 2001 |
Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors.
Topics: Animals; Arteriosclerosis; Chromans; Endothelium, Vascular; Glucuronidase; Hypertension; Kidney; Klo | 2001 |